Evidence map›Paper›PMID 32273608›Full record

ReviewNature medicine2020

Learning from clinical trials of neoadjuvant checkpoint blockade.

Judith M Versluis, Georgina V Long, Christian U Blank

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 140 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
140citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06225284 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

A Randomized Phase II Study of Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients: ESCALATE Study

TypeinterventionalSponsorNational Taiwan University HospitalRan2024 to 2030Enrolled124ConditionsTriple Negative Breast Cancer, Premenopausal Breast CancerArmsGoserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg
NCT07175636 phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation

A Multicenter, Prospective, Phase II Clinical Trial of Short-Course Radiotherapy Followed by QL1706 Plus mFOLFOX6 as Total Neoadjuvant Therapy for Patients With pMMR/MSS Locally Advanced Rectal Cancer

TypeinterventionalSponsorSun Yat-sen UniversityRan2025 to 2029Enrolled66ConditionsLocally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer, Non-metastatic Rectal CancerArmsDrug: QL1706 Drug: mFOLFOX6 Radiation: Short-Course Radiotherapy (SCRT)
3 · Its place in the literature

Who cites it

140 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Neoadjuvant treatment for stage III and IV cutaneous melanoma.The Cochrane database of systematic reviews · 2023
    Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Review
  18. Review
  19. Neoadjuvant therapy in skin cancer: current evidence and future perspectives.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026
    Review
  20. Review

80 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Judith M VersluisDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Georgina V LongMelanoma Institute Australia, The University of Sydney, Sydney, Australia.
Christian U BlankDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. c.blank@nki.nl.ORCID http://orcid.org/0000-0002-7945-5846

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neoadjuvant checkpoint inhibition, in which the therapy is administered before surgery, is a promising new approach to managing bulky but resectable melanoma, and is also being explored in other cancers. This strategy has a high pathologic response rate, which correlates with survival outcomes. The fact that biopsies are routinely available provides a unique opportunity for understanding the responses to therapy and carrying out reverse translation in which these data are used to select therapies in the clinic or in trials that are more likely to improve patient outcomes. In this Perspective, we discuss the rationale for neoadjuvant immunotherapy in resectable solid tumors based on preclinical and human translational data, summarize the results of recent clinical trials and ongoing research, and focus on future directions for enhancing reverse translation.

Indexed as

Antineoplastic Agents, ImmunologicalCell Cycle CheckpointsClinical Trials as TopicHumansImmunotherapyNeoadjuvant TherapyNeoplasmsProtein Kinase InhibitorsAntineoplastic Agents, ImmunologicalProtein Kinase Inhibitors

Identifiers

PMID32273608

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.